BIG DATA

The Middle East has seen the largest growth in infectious disease-related trials over the past decade

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

An analysis of 10 years’ worth of clinical data from GlobalData indicates that infectious disease-related trials have made the biggest strides in the Middle East.

Powered by 

The Middle East has seen an 888% increase in the number of infectious disease trials taking place over the past decade, the largest increase for any region worldwide.

The region now ranks in first for the total number of trials taking place, compared to its sixth-placed ranking in 2010.

These figures come from GlobalData's extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Middle East

The Middle East saw the biggest increase in infectious disease related trials. Between 2010 and 2020, there was a 888% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in Iran with 79.3% of all trials in the region taking place there. Israel and Saudi Arabia had the next largest percentage of trials taking place in the region with 9.1% and 3.4%, respectively.

Asia-Pacific

The Asia-Pacific region saw a 236% increase in the number of infectious disease trials taking place. China saw the largest amount of trials taking place, in 2020, at 43.5%. Trials in India and Australia also made up a large proportion of the trials taking place with 24.6% and 5.6%, respectively.

South and Central America

South and Central America saw a 212% increase in the number trials taking place. Brazil, Argentina and Colombia made up the most trials in the region, with 45.9%, 14.9% and 9.7%, respectively.

Africa

Africa saw a 114% increase in infectious disease related trials taking place. Egypt saw the largest percentage of trials taking place in the region at 24.7%. South Africa and Uganda also made up a significant proportion of the trials taking place.

North America

Despite being placed fifth, North America still saw an increase in the number of infectious disease trials. The region saw a 104% increase in the number of trials. The United States made up 78.3% the largest proportion of trials taking place in the region. Canada and Mexico also made up a large amount of the trials taking place with 11.7% and 10%, respectively.

Europe

Europe saw the biggest decrease in infectious disease trials. The number of trials in the region fell by 97% between 2010 and 2020. Spain saw the largest percentage of trials taking place in the region with 14.9%.

Go to top

Go to top

02/23/2024 20:37:25
  • Home | Mapping the RNA therapeutics R&D landscape in 2022 
  • In this issue
  • Contents
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • Restrictive Medicare coverage spells continued uncertainty for Aduhelm
  • 2021: a record year for orphan therapies
  • Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
  • Mimotopes Company Insight
  • Mimotopes
  • In Depth
  • Mapping the RNA therapeutics R&D landscape in 2022
  • A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?
  • Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!
  • How technology could transform drug research in 2022
  • Anaesthesia drugs worst-hit by US drug shortages
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Data
  • Asia-Pacific sees the largest growth in metabolic disorders-related trials over
  • The Middle East has seen the largest growth in infectious disease-related trials over the past decade
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Baxter
  • Events
  • Next issue
01/20/2022 00:00:00